| |
Neupro® is available in the
European market since March 2006 for the treatment of early
stage idiopathic Parkinson's disease as monotherapy (i.e. without
levodopa). The drug has already been launched by SCHWARZ PHARMA
in Germany, the UK, Austria, Denmark, Ireland, Norway, Switzerland,
Sweden, Greece and Spain.
Neupro®, with the active ingredient rotigotine, is a non-ergoline
dopamine receptor-agonist formulated as a transdermal delivery
system, a patch. The patch is applied to the skin once a day
and provides rotigotine continuously to the body for 24 hours.
It, therefore, covers symptoms not only during the day, but
also at night. Multinational clinical studies with patients
in early and advanced stages of Parkinson's disease have shown
efficacy and safety in Parkinson's disease patients and a potential
for long term benefit. In more than 20 clinical trials, more
than 2,000 patients with early or advanced Parkinson’s
disease have been treated with rotigotine transdermal patch.
Rotigotine exhibits a promising receptor profile, rapid metabolism
and low potential of pharmacokinetic drug-drug interactions.
The patch administration of rotigotine offers the convenience
of once daily-dosing and easy usage.
|